BackInozyme Pharma Overview

Inozyme Pharma Other Liabilities

Track Inozyme Pharma's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Inozyme Pharma Other Liabilities History

Loading

Inozyme Pharma vs. peers: Other Liabilities Comparison

Loading

Inozyme Pharma Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Inozyme Pharma (INZY) FAQ

As of the most recent data (March 2025), INZY shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INZY's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Inozyme Pharma is outperforming or lagging.

Tracking INZY's other liabilities over time shows whether Inozyme Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has Inozyme Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.

Inozyme Pharma's other liabilities is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.